You are here: Industry Insights > Alzheimer’s

News List

Alzheimer’s - Hypotheses & Drug Targets David Orchard-Webb
July 31, 2023
The blood-brain barrier (BBB) is a physical barrier that keeps the extracellular fluid of the brain separate from the bloodstream.
Pharmaceutical News of the Week (July. 6th-July. 10th) | PharmaSources.com - Updates on Approvals PharmaSources/Caicai
July 21, 2020
With the second week of July coming to a close, let’s review the hot events of the pharmaceutical industry this week.The news involved 6 sections: approval, R&D, policies, transactions, listing and miscellany that happened during July 6-10.
NIH study says repurposed cancer therapies beneficial for Alzheimer’s Pharmaceutical-Technology
November 12, 2021
Scientists from the US National Institutes of Health (NIH) unit National Institute on Aging (NIA) have found that present and developing therapies for cancer could potentially...
Thinking impaired in 60% of COVID-19 survivors worldpharmanews
August 02, 2021
In a sample of over 400 older adults in Argentina who had recovered from COVID-19, more than 60% displayed some degree of cognitive impairment, a researcher from The University of Texas Health Science Center at San Antonio reported July 29 at the ...
Alzheimer’s treatment lowers tau by nearly 50 percent in Phase I trials europeanpharmaceuticalreview
July 30, 2021
Biogen and Ionis announced positive topline data on investigational Alzheimer’s treatment, indicating 50 percent tau protein reduction.
Former FDA adviser calls for wider probe into Biogen Alzheimer’s drug approval expresspharma
July 22, 2021
A federal probe of the US Food and Drug Administration’s approval of a controversial new Alzheimer’s disease drug should look into why that decision was made without clear evidence of patient benefit, a former adviser to the agency said 20th.
Biogen gets US FDA accelerated approval for Aduhelm to treat Alzheimer’s expresspharma
June 09, 2021
It is the first new treatment approved for Alzheimer's since 2003 and is the first therapy that targets the fundamental pathophysiology of the disease.
FDA Approves Aducanumab To Treat Alzheimer’s Disease contractpharma
June 09, 2021
The U.S. Food and Drug Administration (FDA) has approved aducanumab, the first drug that slows Alzheimer's disease. Aducanumab is also the first novel therapy for Alzheimer’s disease approved since 2003.
Alzheimer’s drug designed using Exscientia’s AI technology enters clinic pharmatimes
May 17, 2021
An Alzheimer’s disease drug candidate designed using Exscientia’s artificial intelligence (AI) technology has entered Phase I clinical testing, the company announced May 13.
First AI designed Alzheimer’s drug to enter clinical trials europeanpharmaceuticalreview
May 14, 2021
The trial of DSP-0038, an Alzheimer’s disease psychosis drug designed using artificial intelligence, will assess its ability to improve the behavioural and psychological symptoms of dementia.

Previous page 1 2 3 Next page